Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma (NCT07311057) (2025)

Government Record · Daryoush Hamidi Alamdari, PhD (sponsor-investigator) · December 2025

Daryoush Hamidi Alamdari et al., 2025-12: Registered Iranian phase 3 single-arm trial of topical formulated methylene blue in 20 patients with advanced or inoperable squamous cell carcinoma of the skin, stated by the registry to have no comparison group. Status enrolling by invitation; no results posted.

Receive topical methylene blue solution or ointment applied to the affected skin every two days for one month.

Daryoush Hamidi Alamdari et al., 2025-12: Registered Iranian phase 3 single-arm trial of topical formulated methylene blue in 20 patients with advanced or inoperable squamous cell carcinoma of the skin, stated by the registry to have no comparison group. Status enrolling by invitation; no results posted. Record field quote from the registry brief summary, hence MEDIUM. Registry: ClinicalTrials.gov NCT07311057. Sponsor-investigator: Daryoush Hamidi Alamdari, PhD (Mashhad University of Medical Sciences, Iran). Phase 3. Status: ENROLLING_BY_INVITATION. Enrollment 20. Start 2025-12-20; primary completion 2026-01-20. Intervention: topical formulated methylene blue solution or ointment every two days for one month; primary outcome is rate of wound healing and tumour regression. The registry states 'There is no comparison group in this study.' REGISTERED, NO RESULTS POSTED. Note the unusual label: a 20-patient uncontrolled study registered as phase 3. Study type: regulatory record.